不适当的循环利尿剂的处方与通道阻断剂相关的外周胀:从生理学的教训
Jesús Daniel Meléndez-Flores1, Mónica Sánchez-Cárdenas1
1Internal Medicine Department, "Dr. José Eleuterio González" University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
The American journal of the medical sciences
|May 1, 2025
概括
通道阻塞剂 (CCB) 可以引起外周,经常被误认为是液体过载. 这篇文章解释了CCB诱导的胀机制,并提供了帮助医生管理这种常见副作用的策略.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 通道阻塞剂 (CCB) 被广泛用于高血压.
- 周围水会影响到70%的CCB患者.
- 医生经常误解CCB诱导的胀是液体过载.
研究的目的:
- 为了阐明CCB诱导的血管扩张性瘤背后的机制.
- 为了区分CCB胀与液体过载.
- 为CCB诱导的外周水提出管理策略.
主要方法:
- 审查关于CCB药理和副作用的现有文献.
- 分析导致CCB使用的外周胀的生理机制.
- 临床病例审查和指南分析.
主要成果:
- 由于动脉动脉血管扩张而引起的CCB诱导的,而不是系统性液体过载.
- 利尿剂治疗通常是无效的,并可能导致电解质失衡和急性损伤等不良影响.
- 了解血管扩张机制是适当管理的关键.
结论:
- 由CCB诱导的外周主要是药理动力学效应,而不是液体过载的迹象.
- 使用利尿剂的管理不当可能导致严重的并发症.
- 医生应该考虑其他策略来管理CCB诱导的.
相关概念视频
Heart Failure Drugs: Diuretics
277
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
277
Antihypertensive Drugs: Potassium-Sparing Diuretics
398
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
398
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Antihypertensive Drugs: Action of Calcium Channel Blockers
393
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
393
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
674
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
674
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
385
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385


